Akebia Therapeutics Q2 2024 GAAP EPS $(0.04) Beats $(0.05) Estimate, Sales $43.648M Miss $49.450M Estimate
Portfolio Pulse from Benzinga Newsdesk
Akebia Therapeutics (NASDAQ:AKBA) reported Q2 2024 GAAP EPS of $(0.04), beating the $(0.05) estimate, but sales of $43.648M missed the $49.450M estimate. EPS improved by 33.33% year-over-year, while sales decreased by 22.58%.
August 08, 2024 | 11:16 am
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Akebia Therapeutics reported Q2 2024 GAAP EPS of $(0.04), beating the $(0.05) estimate, but sales of $43.648M missed the $49.450M estimate. EPS improved by 33.33% year-over-year, while sales decreased by 22.58%.
While Akebia Therapeutics beat EPS estimates, the miss on sales and the significant year-over-year decline in revenue may offset the positive EPS news, leading to a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100